Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 6/20 | 0.39 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.39 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.39 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | HSP90AA1 | P07900 | 5/20 | 0.37 |
| ▸ | HSP90AB1 | P08238 | 5/20 | 0.37 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7201013 | 0.85 | KDM4E (0.44) | AOC3ALDH1A1HSD17B10ERN1MAPK1 | |
| SCHEMBL16735529 | 0.80 | AOC3 (0.47) | AOC3ALDH1A1HSD17B10TDP1CYP3A4 | |
| SCHEMBL2188123 | 0.80 | AOC3 (0.47) | AOC3ALDH1A1HSD17B10TDP1CYP3A4 | |
| SCHEMBL2188119 | 0.80 | AOC3 (0.47) | AOC3ALDH1A1HSD17B10TDP1CYP3A4 | |
| SCHEMBL1579496 | 0.78 | TDP1 (0.46) | AOC3ALDH1A1HSD17B10TDP1ERN1 | |
| SCHEMBL6936698 | 0.78 | ERN1 (0.42) | AOC3ERN1 | |
| SCHEMBL881447 | 0.77 | NQO2 (0.45) | AOC3ALDH1A1HSD17B10TDP1TXNRD1 | |
| SCHEMBL863397 | 0.77 | AOC3 (0.51) | AOC3ALDH1A1HSD17B10TDP1ERN1 | |
| SCHEMBL22589288 | 0.77 | ALDH1A1 (0.44) | AOC3ALDH1A1HSD17B10TDP1TXNRD1 | |
| SCHEMBL2571759 | 0.77 | ALDH1A1 (0.44) | AOC3ALDH1A1HSD17B10TDP1TXNRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3131539-B1 | SEMICARBAZIDE-SENSITIVE AMINE OXIDASE INHIBITORS FOR USE AS ANALGESICS IN TRAUMATIC NEUROPATHY AND NEUROGENIC INFLAMMATION | PECSI TUDOMANYEGYETEM (HU) | 2018-12-05 | — | — | EP | claimed |
| US-11254647-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2022-02-22 | — | — | US | disclosed |
| EP-3421458-B1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2020-11-11 | — | — | EP | disclosed |
| US-20200317629-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2020-10-08 | — | — | US | disclosed |
| US-10787430-B2 | Hemoglobin modifier compounds and uses thereof | FRONTHERA U.S. PHARMACEUTICALS LLC (US) | 2020-09-29 | — | — | US | disclosed |
| US-10730847-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2020-08-04 | — | — | US | disclosed |
| US-20190330181-A1 | HEMOGLOBIN MODIFIER COMPOUNDS AND USES THEREOF | SICHUAN HAISCO PHARMACEUTICAL CO., LTD. (CN) | 2019-10-31 | — | — | US | disclosed |
| US-20190152937-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2019-05-23 | — | — | US | disclosed |
| EP-3421458-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | Janssen Pharmaceutica NV (BE) | 2019-01-02 | — | — | EP | disclosed |
| US-10155737-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | JANSSEN PHARMACEUTICA NV (BE) | 2018-12-18 | — | — | US | disclosed |
| US-20110263567-A1 | COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES | SEMMELWEIS EGYETEM (HU) | 2011-10-27 | — | — | US | disclosed |
| US-20110263567-A1 | COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES | SEMMELWEIS EGYETEM (HU) | 2011-10-27 | — | — | US | disclosed |
| EP-2342179-A1 | COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES | Semmelweis Egyetem (HU) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010029379-A1 | COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES | SEMMELWEIS EGYETEM (HU) | 2010-03-18 | — | — | WO | disclosed |
| WO-2010029379-A1 | COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES | SEMMELWEIS EGYETEM (HU) | 2010-03-18 | — | — | WO | disclosed |
| US-6353002-B2 | DIOXINOINDOLE AND THIENOBENZODIOXIN COMPOUNDS WHICH ARE HT3 RECEPTOR ANTAGONISTS AND ARE USED TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS | KNOLL AKTIENGESELLSCHAFT (DE) | 2002-03-05 | — | — | US | disclosed |
| US-20010008903-A1 | Therapeutic agents | BIRCH ALAN MARTIN (GB) | 2001-07-19 | — | — | US | disclosed |
| US-6201004-B1 | CENTRAL NERVOUS SYSTEM, PSYCHOLOGICAL, EATING, CARDIOVASCULAR, BRAIN, AND GASTROINTESTINAL DISORDERS | KNOLL AKTIENGESELLSCHAFT (DE) | 2001-03-13 | — | — | US | disclosed |
| EP-0966470-A1 | DIOXINO DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | KNOLL AKTIENGESELLSCHAFT (DE) | 1999-12-29 | — | — | EP | disclosed |
| WO-1998040386-A1 | DIOXINO DERIVATIVES AND THEIR USE AS THERAPEUTIC AGENTS | KNOLL AKTIENGESELLSCHAFT (DE) | 1998-09-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263567-A1 | COMPOUNDS FOR INHIBITING SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) / VASCULAR ADHESION PROTEIN-1 (VAP-1) AND USES THEREOF FOR TREATMENT AND PREVENTION OF DISEASES | VCAM1, AOX1, AOC3 | AOC3 3/4885ALDH1A1 44/4885HSD17B10 926/4885 |
| US-10155737-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | GPR119, GPR180, GPR55 | AOC3 2750/4885ALDH1A1 2452/4885HSD17B10 568/4885 |
| US-20200317629-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | GPR119, GPR180, GPR55 | AOC3 2750/4885ALDH1A1 2452/4885HSD17B10 568/4885 |
| US-20190152937-A1 | BENZO-FUSED HETEROCYCLIC DERIVATIVES USEFUL AS AGONISTS OF GPR120 | GPR119, GPR180, GPR55 | AOC3 2750/4885ALDH1A1 2452/4885HSD17B10 568/4885 |
| US-20190330181-A1 | HEMOGLOBIN MODIFIER COMPOUNDS AND USES THEREOF | HBB, HBG1, HBG2 | AOC3 2690/4885ALDH1A1 863/4885HSD17B10 722/4885 |
| US-10787430-B2 | Hemoglobin modifier compounds and uses thereof | HBB, HBG1, HBG2 | AOC3 2690/4885ALDH1A1 863/4885HSD17B10 722/4885 |
| US-11254647-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | GPR119, GPR180, GPR55 | AOC3 2750/4885ALDH1A1 2452/4885HSD17B10 568/4885 |
| US-10730847-B2 | Benzo-fused heterocyclic derivatives useful as agonists of GPR120 | GPR119, GPR180, GPR55 | AOC3 2750/4885ALDH1A1 2452/4885HSD17B10 568/4885 |
| US-20010008903-A1 | Therapeutic agents | GPR119, SNCA, HTR2B | AOC3 1931/4885ALDH1A1 3243/4885HSD17B10 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.